




IMMUNO-ONCOLOGY INSIGHTS

Your content marketing partner for life sciences

MEDIA KIT 2024



INDEX

Your content
marketing
partner for life
sciences

▶ About	3
▶ What can we do for you?	5
▶ User demographics	7
▶ Editorial calendar	11
▶ Testimonials	13
▶ Opportunities	14
▶ Webinars	15
▶ Expert roundtables	18
▶ Articles	19
▶ Interviews & podcasts	20
▶ Video presentations	22
▶ Infographics	24
▶ Scientific illustrations	25
▶ eBlasts	26
▶ Premium services	27
▶ Our other publications	28

ABOUT

Immuno-Oncology Insights

Immuno-Oncology Insights is an online only, independent, peer-reviewed open access journal covering the entire cancer immunotherapy space from preclinical to clinical development. Critical topics include tools and technologies, biomarkers, the TME, combination therapy, platform development trends and safety. Challenges and advances are addressed through publication of original research, reviews, commentary articles, clinical trial reports and so much more.

All content is available free of charge, and the written material is complemented by engaging formats such as webinars, infographics, animations, video and podcasts.


An online only, peer reviewed, open access journal covering the entire cancer immunotherapy space from pre-clinical to clinical development

2023



SPOTLIGHT ON
Overcoming mechanisms of tumor resistance part 2:
what progress is being made in solid tumors?

Guest Editor
Brent Hanks, William Dalton, Family Assistant Professor of Medical Oncology at Duke University with
a dual appointment with the Duke Cancer Institute




Is it important for **your company to demonstrate its capabilities** to scientists and/or business leaders making key technology platform decisions at an early stage in a product's development?

Do you need to **generate qualified leads** from companies involved in the development of cancer immunotherapies?

Are you looking to **provide educational materials** to individuals focused on analysis, tools, technologies, preclinical and clinical development?

***Immuno-Oncology Insights* provides a unique online content marketing and lead-generation opportunity:**

- ▶ **Active engagement of key stakeholders** from across the global community all year round
- ▶ The chance to **target organizations at varying stages of the R&D pipeline**: Large pharma-mid sized pharma, biotech, spin-outs, research and academic institutions, hospital, investors and analysts
- ▶ **An alternative to the ever-more expensive conference market**
- ▶ A means by which you can access those individuals driving the ongoing translation of safe, effective immuno-oncology therapeutics on a global basis



Immuno-Oncology Insights provides a unique online content marketing and lead-generation opportunity

WHAT CAN WE DO FOR YOU?

We can:

- ▶ Provide support in the **development of your content marketing strategy** and tactics for this sector, partnering with you in the development of your annual marketing plans
- ▶ Work closely with you to **create quality written, video and audio content** of high value to your target audience
- ▶ Offer you opportunities to **re-purpose scientific and educational content** you have already developed and make it available to a global audience
- ▶ **Raise your company's profile**, demonstrate your capabilities, and enhance your reputation as a thought-leader in the sector
- ▶ Play a key role in your **lead-generation activities**
- ▶ Ensure your leading scientists are seen as **Subject Matter Experts** throughout your target market
- ▶ **Create written content from video or audio**, ideal for increasing the reach, longevity and searchability of your data and other technical information

We don't sell off-the-shelf solutions. All the packages we provide are tailored to your precise marketing, educational and business development objectives.

We can partner with you to develop high quality content to demonstrate your thought-leadership:


- ▶ Your own special focus issue or ebook on the topic of your choice
- ▶ Client case studies, interviews and co-presentations
- ▶ Peer reviewed articles, as well as editorials and commentaries
- ▶ Video presentations and roundtables
- ▶ Podcasts
- ▶ Infographics and animations
- ▶ Webinars, both live and on demand




USER DEMOGRAPHICS

Data by sector


- ▶ Immunotherapy approaches have transformed cancer treatment. This has resulted in increased investment in the immuno-oncology space to meet the need for both new drugs, and cutting-edge products, technologies to support further innovation
- ▶ *Immuno-Oncology Insights* offers an unparalleled opportunity to target all the key stakeholders involved in driving the ongoing translation of safe, effective I-O therapeutics.
- ▶ Prolific academic institutions and research hospitals, in particular those that generate spin-outs based on cancer immunotherapy candidates and technologies
- ▶ Pharmaceutical companies and large biotechs with a major or growing focus on immuno-oncology
- ▶ Government-funded organizations (such as NIH) and NGOs
- ▶ Investors and analysts




29%
Biotech



22%
Academic/
Hospital



21%
Pharma/
Large Biotech



3%
Government/
NGO



2%
Investor/
Analyst



22%
Solution/
Service Provider,
including CROs




1%
Consultant

We
currently
have 13,000
registered
users


Data by interest area & seniority

- ▶ Discovery and basic research
- ▶ Preclinical development and translational R&D
- ▶ Clinical research
- ▶ Product development, process development, operations, logistics and manufacture
- ▶ Regulatory affairs, QA/QC and validation
- ▶ Business development, corporate management and licensing

Immuno-Oncology Insights covers the entire cancer immunotherapy space from from preclinical to clinical development and the latest tools and technologies, featuring content of value to individuals along the R&D pipeline



Data by interest area & seniority (continued)



Data by location



EDITORIAL CALENDAR



Spotlights

Each monthly Spotlight focuses BioInsights members' attention on a particular topic or technology area. We leverage an array of formats to provide a comprehensive update on the key trends, challenges and breakthroughs in a given field: Independently peer reviewed Expert Insights, Opinion pieces, Interviews, Webinars, Podcasts, FastFacts videos, and more...



Podcast series

We select a key issue or challenge, then invite a range of stakeholders to proffer their opinions and share related learnings via the ever-popular, easy-to-consume podcast format.

You are able to sponsor any of the Spotlights and/or select an issue for the content we develop together.

We also feature a Tools & Technologies channel on our website where your content can be featured.

SPOTLIGHT DETAILS

FEBRUARY	MARCH	APRIL	MAY
<p>Assessing the evolving I-O landscape: key challenges and opportunities for 2024</p> <ul style="list-style-type: none"> ▶ Progress being made in solid tumors ▶ Are cancer vaccines back from the dead? ▶ What's next for checkpoints? ▶ What will the development of biosimilars mean for the field? ▶ Investor, financial, and market access trends 	<p>Combination therapy development</p> <ul style="list-style-type: none"> ▶ Are multimodality approaches the future of the field? ▶ With combination trials proving complex and expensive, how can resources best be deployed/trial design be optimized? ▶ Combinations in solid tumors—opportunities and challenges ▶ Safety considerations: will synergistic effect also result in synergistic toxicity? 	<p>Solving the challenges of solid tumors</p> <ul style="list-style-type: none"> ▶ Translating successes in blood cancer into the solid tumor space ▶ Understanding and addressing mechanisms of tumor resistance ▶ Understanding and overcoming barriers posed by the TME 	<p>Translational insights: bridging the gap from preclinical R&D to the clinic</p> <ul style="list-style-type: none"> ▶ What is going wrong between preclinical <i>in vitro/in vivo</i> settings and clinical <i>in vivo</i> settings? ▶ What model systems can predict patient response to investigational molecules in practice? ▶ How can current <i>in vitro</i> models be improved to better represent the complexity of the tumor, immune system, and surrounding tissue? ▶ What lessons can be drawn from previous negative outcomes from preclinical studies?
JULY	SEPTEMBER	OCTOBER	NOVEMBER
<p>Clinical development strategy</p> <ul style="list-style-type: none"> ▶ Clinical trial design innovation ▶ Dose selection and optimization ▶ Assessing the shifting regulatory landscape ▶ How can the I-O community work to increase global patient access? ▶ Increasing diversity and including the patient voice in clinical trial strategy and planning 	<p>Improving patient selection and stratification</p> <ul style="list-style-type: none"> ▶ Monitoring response and predicting outcome—how can different streams of data (pathology, ctDNA, radiology, etc.) be better harnessed and combined? ▶ Novel biomarker discovery and development ▶ Patient selection and precision medicine strategies ▶ Improved methods of early detection and early detection of relapse 	<p>Addressing ongoing safety and toxicity issues</p> <ul style="list-style-type: none"> ▶ Achieving the greatest benefit with the least toxicity ▶ How can we target tumor cells more accurately? ▶ Most solid tumor antigens are not restricted—are there subsets of targets that can be more specific? ▶ Mechanisms of anti-tumor activity and toxicity in I-O ▶ Does the field need to better manage toxicity with existing therapies, or find new targets and approaches? 	<p>Tools and trends of tomorrow</p> <ul style="list-style-type: none"> ▶ Exploring key enabling technology and platform innovation trends and advances for the year(s) to come

TOOLS & TECHNOLOGIES FOCUS

MARCH	JUNE	DECEMBER
<p>Practical considerations for cutting edge tech</p> <ul style="list-style-type: none"> ▶ How can tools such as AI be embedded into prospective ongoing clinical trials? ▶ As data science becomes increasingly important, how can we integrate/educate data scientists and cancer immunologists? ▶ Are tools like spatial omics practical and usable yet? 	<p>Turning data into knowledge</p> <ul style="list-style-type: none"> ▶ How can emerging tools help to integrate and combine information from different sources and spanning different scales? 	<p>Preclinical tools update</p> <ul style="list-style-type: none"> ▶ Addressing lack of translatability from preclinical activity ▶ How can the field pick out the best candidates earlier and save crucial time and resources? ▶ Making models more applicable for safety and efficacy

TESTIMONIALS



Testimonials

- ▶ This is what **HUB Organoids** had to say about *Immuno-Oncology Insights* after working together on a webinar

“We are getting good traction on the Immuno-oncology Insights front at HUB. The webinar hosted by *Immuno-Oncology Insights* generated a good number of leads that we are now nurturing, but also gave us the opportunity to assess and re-evaluate our offerings and capabilities. I feel more confident now and will be seeing assets and promos coming up because of the webinar. We will be using *Immuno-Oncology Insights* throughout this year and in 2023 to help us with our marketing campaign to increase awareness and lead generation for HUB. I worked with other digital media publications this year, but I find the quality of the *Immuno-Oncology Insights* leads to be better aligned to our current needs at HUB Organoids.”

- ▶ Testimonial from guest editor **Dr Pelin Candarlioglu, Senior Cell Biologist at GSK and Chair of Industry Advisory Board at EUROoCS**

“I had an interest in immuno-oncology and cell therapies long before I could start working with them and during that time I was reading a lot of articles from BiInsights. It is very nice to know I might be able to contribute to the next generation’s interest in the field.”

IOI Editorial Advisory Board

- ▶ *Immuno-Oncology Insights* (Senior Editors: **Dr Jon Wigginton, Dr Renier Brentjens**) is an independently peer reviewed, open access journal for debate and discussion by all stakeholders involved in driving the ongoing translation of safe, effective I-O therapeutics. Our editions are strongly guided by our Editorial Advisory Board, which features a number of high-profile figures within academia and industry:
- ▶ **Fernanda I. Arnaldez MD**
Executive Global Product Leader—Early Development, Oncology Research and Development, AstraZeneca
- ▶ **Roy D. Baynes MD PhD**
Senior Vice President and Head, Global Clinical Development, Chief Medical Officer, Merck Research Laboratories
- ▶ **John Desjarlais PhD**
CSO, Xencor
- ▶ **David J. DiLillo PhD**
Associate Director, Oncology/Angiogenesis, Regeneron Pharmaceuticals
- ▶ **Dr Rakesh Dixit**
President & Chief Executive Officer, Bionavigen
- ▶ **Dr Jessica Flechtner**
CSO, Genocea Biosciences
- ▶ **Anurag Khetan PhD**
Senior Director, Global Cell Line Development and Omics, Bristol-Myers Squibb

OPPORTUNITIES

We offer a broad range of options to help you reach your target audience, any of which can be tailored to match your current marketing and business development priorities. These include interviews, expert roundtables, podcasts, webinars, articles, video presentations, infographics, eblasts and more.

Any of our options can be tailored to match your current marketing and business development priorities.



WEBINARS

Presenting a webinar with *Immuno-Oncology Insights* gives you an efficient and cost-effective way to:

- ▶ Generate qualified leads from amongst the global immuno-oncology community
- ▶ Demonstrate your company's expertise and capabilities
- ▶ Stimulate discussion around a topic of significant importance to your customers
- ▶ Educate individuals on crucial regulatory, scientific or technical issues
- ▶ Make a noise around a new product or service offering launch

Webinars can stand alone or can be included in a Spotlight, depending on the topic and timing fit.

Our
2024
webinar
schedule is
filling up fast.

Contact jamie.cox@insights.bio to
discuss options & availability.



Presenting a webinar with us is an efficient and cost-effective way to generate qualified leads.

Our webinar packages include:

- ▶ As much support as you need in terms of topic selection and agenda development, format selection, and speaker panel identification and invitation
- ▶ Full hosting and technical support, including planning calls with panellists and rehearsals as needed
- ▶ A comprehensive promotional plan, including multiple email shots to our database, website and newsletter marketing, and social media
- ▶ A moderator from our editorial team to ensure the webinar runs smoothly on the day
- ▶ Registration and attendee lists for the webinar
- ▶ A report on the questions submitted during the live webinar so you can follow up directly with individuals afterwards and continue the discussion
- ▶ Hosting of the webinar recording on an indefinite basis with ongoing lead generation
- ▶ Webinar recording provided to you for hosting on your own site
- ▶ The option for us to publish an article based on the transcript of the webinar, repurposing your presentation into written format and making it search engine friendly

We don't sell off-the-shelf solutions. All the packages we provide are tailored to your precise marketing, educational and business development objectives.

Examples of previous webinars for our clients:

This screenshot shows a webinar panel-style article. At the top left, it indicates the date 'Feb 3 2022' and the event 'ONCEMIND'. The main title is 'The digital revolution: Technological innovations to enable automation in cell therapy manufacturing'. The sponsor is 'Thermo Fisher Scientific'. The article is titled 'CELL & GENE THERAPY INSIGHTS' and 'INNOVATOR INSIGHT'. The main text reads: 'The digital revolution: technological innovations to enable automation in cell therapy manufacturing'. The authors are 'Sean Chang, Bruce Grossmuller & Kish Roy'. The article includes a 'Watch now' button and a 'Download transcript' button. The page number '355' is visible at the bottom.

Panel-style webinar with accompanying transcript-based article for Thermo Fisher Scientific

This screenshot shows a webinar presentation-style article. At the top left, it indicates the date 'May 5 2022' and the event 'ONCEMIND'. The main title is 'Process development excellence to de-risk and accelerate commercialization of cell and gene therapies'. The sponsor is 'Lonza Cell & Gene'. The article includes a 'Watch now' button and a 'Download transcript' button. The speaker is 'Behnam Baghbaderani, Global Head, Process Development, Emerging Technologies at Lonza Pharma & Biotech'. The page number '356' is visible at the bottom.

Presentation-style webinar with Q&A for Lonza

This screenshot shows a 'Live30' webinar article. At the top left, it indicates the date 'Feb 10 2022' and the event 'ONCEMIND'. The main title is 'TESSA technology: A new era for AAV manufacture'. The sponsor is 'OXGENE, A VBL Associated Company'. The article includes a 'Watch now' button and a 'Download transcript' button. The speaker is 'Ryan Cawood, Chief Scientific Officer at OXGENE'. The page number '357' is visible at the bottom.

Live30 webinar: a 30 minute webinar focused on new technologies and their applications for OXGENE

You can view all of our on-demand webinars here.

EXPERT ROUNDTABLES

On-demand video expert roundtables provide powerful tools for you to generate qualified leads and/or position your thought-leader(s) at the heart of the debate around a topic of key importance to your company.

Our editorial team works closely with you to identify over-arching topics and discussion points, and to convene a panel of KOLs. We then liaise with the panel to define the final list of questions for discussion, video and edit the roundtable itself, and then produce a full article based on the transcript.



Video roundtable examples:



Video




Article

Expert Roundtable: leveraging cutting edge tools to convert I-O data into knowledge



Video and article



Poster summarising key learning points

Strategies for scaling up and out in gene therapy manufacturing: addressing AAV's growing pains (for Corning)

ARTICLES

Free access publication of submitted articles remains the gold standard for sharing data with scientists across the sector.

Our sponsored article publication package includes full peer review, a license for you to reproduce the article on your own website, and a comprehensive two-month promotional package to maximise readership.

Examples of articles for our clients:

VECTOR BIOPROCESSING

Clarification of recombinant adeno-associated virus (rAAV) & lentivirus from adherent culture for Pall Biotech

Cell & Gene Therapy Insights 2022; 8(3): 483–493
DOI: 10.18609/cgti.2022.070

RESEARCH ARTICLE

Rajeshwar Chinnawar, Nicholas Marchand

In recent years the cell and gene therapy industries have been rapidly expanding, with two adeno-associated virus (AAV) and lentivirus. With clinical success comes the need to develop processes. As both of these vectors are produced in cells, the first step in their purification many technologies traditionally used for cell culture clarification but given the projected consumables a combination of depth and membrane filtration is a logical fit for batch processes.

CELL & GENE THERAPY INSIGHTS

FIGURE 2 — Performance metrics of the Pall Biotech clarification process. The graph shows the percentage of virus remaining after clarification for rAAV and lentivirus. The y-axis represents the percentage of virus remaining, ranging from 0 to 100. The x-axis represents the clarification process steps. The legend indicates rAAV (blue) and lentivirus (green). The data shows that the clarification process maintains high recovery rates for both virus types, with rAAV recovery consistently above 90% and lentivirus recovery above 80%.

488

Clarification of recombinant adeno-associated virus (rAAV) & lentivirus from adherent culture for Pall Biotech

ANALYTICS: Enhancing accuracy & throughput

Accelerating AAV capsid analysis using a new multi-capillary electrophoresis platform for SCIEX

Cell & Gene Therapy Insights 2022; 8(2): 231–240
DOI: 10.18609/cgti.2022.039

INNOVATOR INSIGHT

Susan Darling

Adeno-associated viral (AAV) vectors, while offering numerous advantages over other viruses (non-pathogenic, low immunogenicity, and can readily enter a variety of cell types), are highly complex molecules that present significant manufacturing challenges. There are a large number of serotypes to choose from, and the need to implement transfection processes that afford high yields of capsids containing the gene of interest and purification hurdles to overcome. From an analytical perspective, samples are getting more complex, more numerous, and require more complex analytical methods that involve complex method set ups, but results are needed in less time. Despite these challenges, developers of gene therapies must be able to understand the molecular liabilities of AAV vectors as soon as possible in the

Accelerating AAV capsid analysis using a new multi-capillary electrophoresis platform

Cell & Gene Therapy Insights 2022; 8(2): 231–240
DOI: 10.18609/cgti.2022.039

INNOVATOR INSIGHT

Susan Darling

Adeno-associated viral (AAV) vectors, while offering numerous advantages over other viruses (non-pathogenic, low immunogenicity, and can readily enter a variety of cell types), are highly complex molecules that present significant manufacturing challenges. There are a large number of serotypes to choose from, and the need to implement transfection processes that afford high yields of capsids containing the gene of interest and purification hurdles to overcome. From an analytical perspective, samples are getting more complex, more numerous, and require more complex analytical methods that involve complex method set ups, but results are needed in less time. Despite these challenges, developers of gene therapies must be able to understand the molecular liabilities of AAV vectors as soon as possible in the

Accelerating AAV capsid analysis using a new multi-capillary electrophoresis platform for SCIEX

CELL THERAPY CMC AND QUALITY CONTROL

Characterization of a novel high-throughput, high-speed based image cytometric cell counting method for Nexcelom

Cell & Gene Therapy Insights 2021; 7(4): 427–447
DOI: 10.18609/cgti.2021.070

RESEARCH ARTICLE

Jordan Bell, Yongyang Huang, Henry Qazi, Dmitry Kuksin, Jian Qiu, Bo Lin, Leo Li

Bioprocessing applications for cells and biologics have dramatically increased the number of immunotherapy. The cell counting time is a major bottleneck for traditional counting methods. Here we characterize and demonstrate a high-throughput, high-speed and high-precision system. Here we characterize and demonstrate a high-throughput cell counter in bright field and fluorescence imaging modes. The system was validated using microbeads, Jurkat and CHO-S cells. We investigated the bead cell counting method.

CELL & GENE THERAPY INSIGHTS

FIGURE 4 — Experimental design and results comparing the CellCount™ HD system to the traditional cell counting method. (a) Schematic of the experimental design showing the comparison of CellCount™ HD (blue) and traditional cell counting (red) across different cell types and conditions. (b) Bar chart showing the cell counting results for CellCount™ HD (blue) and traditional cell counting (red) across different cell types and conditions. (c) Bar chart showing the cell counting results for CellCount™ HD (blue) and traditional cell counting (red) across different cell types and conditions.

TABLE 4 — Validation of the CellCount™ HD system for cell counting. The table shows the mean cell count, standard deviation, and coefficient of variation for different cell types and conditions.

Cell Type	Condition	Mean Cell Count	Standard Deviation	Coefficient of Variation
CHO-S	1	1.00	0.05	5.0%
CHO-S	2	1.00	0.05	5.0%
CHO-S	3	1.00	0.05	5.0%
CHO-S	4	1.00	0.05	5.0%
CHO-S	5	1.00	0.05	5.0%
CHO-S	6	1.00	0.05	5.0%
CHO-S	7	1.00	0.05	5.0%
CHO-S	8	1.00	0.05	5.0%
CHO-S	9	1.00	0.05	5.0%
CHO-S	10	1.00	0.05	5.0%

440

Characterization of a novel high-throughput, high-speed and high-precision plate-based image cytometric cell counting method for Nexcelom

INTERVIEWS & PODCASTS

Interviews are a great way to raise awareness within the immuno-oncology community, with minimal resource requirements from your team.

We can interview up to three of your scientists, executives, partners or clients, with the resulting video, podcast and/or written version included in an issue of the online journal.

Examples of previous interviews for our clients:

Video and written

[Stepping foot into a successful partnership to support your viral vector therapy through commercialization for Merck](#)

VECTORS: Downstream Bioprocessing

Stepping foot into a successful partnership to support your viral vector therapy through commercialization for Merck

Cell & Gene Therapy Insights 2021; 7(11): 1706-1710
10.18609/cgti.2021.225
PUBLISHED: 12 JANUARY 2022

Minh Hong, Marc Gaal

Charlotte Barker, Editor, Cell and Gene Therapy Insights, speaks to Minh Hong, Head of Commercialization, and Marc Gaal, Director, Program Management at the Life Sciences Business Sector, Merck.

Minh Hong leads the commercial team for Viral Gene Therapy contract Business Sector of Merck. He is responsible for account management,...

INTERVIEW

Q: We were the process our customer, process, and our process, which is the...
A: "A robust manufacturing process requires process development output at every stage of the product lifecycle."
Minh Hong

Q: Once you understand the customer's needs, how do you support them through the manufacturing process?
MC: Once the manufacturing process is established, it is critical to ensure that the customer's needs are met...
Q: How would you describe your organization's approach to viral vector manufacturing?
MC: Our new upstream gene therapy manufacturing facility is composed of...
Q: What role does your organization play in determining the right time to invest in a new gene therapy manufacturing facility?
Cell & Gene Therapy Insights | ISSN 2099-7900 | 1707

Podcast and written

[Precisely for CGT: automating aseptic filling for lowest volumes for Single Use Support](#)

SUPPLY CHAIN: Best practices for ensuring cell and gene therapy supply chain scalability

Precisely for CGT: automating aseptic filling for lowest volumes for Single Use Support

Cell & Gene Therapy Insights 2022; 8(3): 403-408
DOI: 10.18609/cgti.2021.059
PUBLISHED: 27 MARCH 2022

PODCAST

Barbara Fischer

Roisin McGuigan, Editor, Bioinsights, speaks to Barbara Fischer, Process Consultant, Single Use Support, Merck.

"...do not be afraid of digital transformation. Follow the opportunities that...

PODCAST INTERVIEW

Q: What specific trends are you seeing currently in the selection of process and equipment?
BF: Certain capabilities are...
Q: How do you see the future of digital transformation in the industry?
Cell & Gene Therapy Insights | ISSN 2099-7900 | 405

Podcasts
in a variety
of formats and
lengths can also be
produced, either in
series or as
one-offs



Key factors to consider for successful cell therapy manufacturing: a case study

Cell & Gene Therapy Insights 2022; 8(2): 241-249
10.18609/cgti.2022.039
PUBLISHED: 2 MARCH 2022

Valentina Becherucci, Øystein Åmellem, Xavier de Mollerat du Jeu

You can listen to the **podcast at the bottom of this page** or read the interview below

[View pdf](#)

PODCAST INTERVIEW

QA: That makes sense. When you have a four-week manufacturing time, that means that the cells are undergoing several passages. Do you have criteria for how many passages you run in your manufacturing process, in order to not lose the cells' characteristics? Do you count the number of passages or the way you get to the desired end point of your drug?

VB: The data of all cultures comes out after process validation. The goal is to reach the therapeutic design. The culture can be shorter - you can stop it at three weeks and use four weeks. It can be longer than four weeks because, according to the literature, if you culture for more than that or five weeks, you can get some unwanted effects on cells. For example, you can get genetic variation that is not good for the patient. The four weeks come from our process validation, where we produced five batches of MSCs, and in four batches we saw that the variability was low in terms of the number of cells after four weeks of culture. We also checked other parameters of MSCs, for example the antigen expression of specific markers that must be positive or negative according to International Society of Cell Therapy.

XMJ: Valentina, in this four-week process, how do you ensure you maintain sterility? Do you do weekly QC monitoring on your process?

VB: In our process, we perform initial sterility before starting the culture directly on the bioreactor. Then, we perform an in-process control of sterility after two weeks of culture, and at the end of the culture, before freezing. In our process, cells will be frozen after four weeks of culture and then moved to liquid nitrogen until you get the patient. In this case, the sterility is performed both on cells and on the cell culture media, on the equipment.

Q DH: What are the QC or analytical tests you implement in your process to ensure the safety and quality of the product?

VB: According to the regulatory specification, the testing methods must be validated, and mandatory regular testing includes testing of the sterility, endotoxin, mycoplasmas, and hermesites, and in our case we also perform cell identification with flow cytometry. All these tests are performed as in-process control at different steps of the process, and also for the final release or the end of the process.

QA: Valentina - as you are using flasks, you operate in Class A cell culture conditions. I see you used bags, or a more closed system that you could operate in a hood?


VB: We have tested different kinds of flasks with more surface for culture. However, we do not use bags. Bags are only used in the final step for freezing and storage in liquid nitrogen. We only use open systems and flasks.

XMJ: You mentioned it is a Phase 2 process. As you move to Phase 3 and commercial, you will need to scale this process. How are you thinking about doing that?

Cell & Gene Therapy Insights | ISSN 2029-7900 | 243

For example:

Key factors to consider for successful cell therapy manufacturing: a case study for Thermo Fisher Scientific



VIDEO PRESENTATIONS

Our FastFacts videos are 10–15 minute edited presentations, accompanied by a poster summarising the key learning points. They are designed for the presentation of app notes, validation data, case studies, scientific posters or product demonstrations, and work well both for educational purposes and for lead generation.



Here are some examples:

FASTFACTS

A demonstration of the Cocoon® platform: a bespoke solution to minimize manual touchpoints in cell therapy manufacturing

Cell & Gene Therapy Insights 2021; 7(10), 389
 10.18609/igti.2021.064
 PUBLISHED: 21 APRIL 2021

FASTFACTS

Joseph O'Connor

Watch the demonstration video or read the poster therapy manufacturing by minimizing manual touchpoints

- ▶ Sample loading
- ▶ Activation
- ▶ Transduction or transfection
- ▶ Expansion
- ▶ Harvest

FASTFACTS

A demonstration of the Cocoon® platform: a bespoke solution to minimize manual touchpoints in cell therapy manufacturing

The Cocoon® platform is a bespoke solution to minimize manual touchpoints in cell therapy manufacturing. It is designed to reduce the risk of contamination and improve the efficiency of the manufacturing process. The platform consists of a series of interconnected modules that allow for the automated production of cell therapy products. The Cocoon® platform is a key component of Lonza's Cell & Gene Therapy solutions.

Lonza

A demonstration of the Cocoon® platform: a bespoke solution to minimize manual touchpoints in cell therapy manufacturing for Lonza

FASTFACTS

Leveraging oncology gene expression signatures to accelerate research

Immuno-Oncology Insights 2022; 3(7), 357
 DOI: 10.18609/oi.2022.037
 PUBLISHED: 2 JULY 2022

FASTFACTS

Sarah Church

RNA signatures are at the forefront of cancer research and bench to the clinic.

In this video and poster from Immuno-oncology Insights, Sarah Church, Senior Director, Research Technology, discusses the use of RNA signatures to accelerate research and bench to the clinic. The video and poster focus on the use of RNA signatures to identify key biological themes and to accelerate the development of new therapies. The video and poster also discuss the use of RNA signatures to identify key biological themes and to accelerate the development of new therapies.

Watch the video, read the scientific poster, or submit your own video or poster.

- ▶ Panels with clinically, analytically, and biologically essential interpretation of data
- ▶ Research signatures focusing on biological themes including stromal factors, inhibitory immune signaling, and immune exhaustion
- ▶ The framework and processes that went into developing the research signatures

FASTFACTS

Leveraging oncology gene expression signatures to accelerate research

RNA signatures are at the forefront of cancer research and bench to the clinic. In this video and poster from Immuno-oncology Insights, Sarah Church, Senior Director, Research Technology, discusses the use of RNA signatures to accelerate research and bench to the clinic. The video and poster focus on the use of RNA signatures to identify key biological themes and to accelerate the development of new therapies. The video and poster also discuss the use of RNA signatures to identify key biological themes and to accelerate the development of new therapies.

NanoString

Leveraging oncology gene expression signatures to accelerate research for NanoString

FASTFACTS

Driving CAR-T from early-stage development to clinical filing and lot release

Cell & Gene Therapy Insights 2022; 8(5), 793
 DOI: 10.18609/igti.2022.110
 PUBLISHED: 11 JULY 2022

FASTFACTS

Ulrike Herbrand, Julia Schueler, Sophie Vermond

Driving CAR-T from early-stage development to clinical filing and lot release

- ▶ Approach to assess the efficacy, potency, persistence, and safety of CAR-T in vivo
- ▶ Evaluating the efficacy and safety profile of CAR-T in vivo
- ▶ Share regulatory expectations (guidelines and how to integrate them into development that reflect the MoA and are able to meet them)
- ▶ Discuss biological activity assays at play for CAR-T and how they play a key role in defining the quality of the product

FASTFACTS

Driving CAR-T from early-stage development to clinical filing and lot release

Ulrike Herbrand, Julia Schueler, Sophie Vermond, Charles River Laboratories

Driving CAR-T from early-stage development to clinical filing and lot release. This article discusses the challenges of driving CAR-T from early-stage development to clinical filing and lot release. It covers the approach to assess the efficacy, potency, persistence, and safety of CAR-T in vivo, the evaluation of the efficacy and safety profile of CAR-T in vivo, the sharing of regulatory expectations (guidelines and how to integrate them into development that reflect the MoA and are able to meet them), and the discussion of biological activity assays at play for CAR-T and how they play a key role in defining the quality of the product.

Charles River Laboratories

Driving CAR-T from early-stage development to clinical filing and lot release for Charles River Laboratories

FASTFACTS

T cell characterization in 3D cell models using advanced flow cytometry

Immuno-Oncology Insights 2021; 2(4), 207
 10.18609/oi.2021.028
 PUBLISHED: 12 JULY 2021

FASTFACTS

Miniver Oliver

Watch the video or read the poster to learn:

- ▶ Why advanced cell models and advanced high throughput flow cytometry are essential for T cell characterization in 3D spheroids
- ▶ How the IQon® platform, kits and fully validated spheroid dissociation protocols are used for T cell characterization in 3D spheroids
- ▶ How multiparametric analysis using IQon® T cell characterization kits is used for T cell characterization in 3D spheroids

FASTFACTS

T cell characterization in 3D cell models using advanced flow cytometry

Miniver Oliver is a Senior Scientist at Sartorius, Bio Analytics research team. Over the past 5 years, she has been instrumental in the development and validation of the IQon® Live Cell Analysis System Advanced Flow Cytometry Platform. Miniver is currently focused on the development and compound screening of T cell characterization in 3D spheroids.


Sartorius

T cell characterization in 3D cell models using advanced flow cytometry for Sartorius

Our FastFacts work well for educational and lead-generation purposes

INFOGRAPHICS

Our team are experts in communicating complex scientific information via visual formats, including infographics (static, voiced and animated), PPT presentations and illustrations. They work closely with your team to define contents and style, and the resulting content can be published in *Immuno-Oncology Insights* or simply provided to you for your own use.



Examples include:

Voiced infographic





[Manufacturing and analytics for lentivirus and AAV vectors: a visual and audio guide for Thermo Fisher Scientific](#)

Animated infographic

[Regulatory FAQs & common concerns for cell & gene therapy raw and starting materials for Thermo Fisher Scientific](#)



SCIENTIFIC ILLUSTRATIONS



We work from your sketch or concept to create schematics or illustrations of your products or services

eBLASTS

We offer a strictly limited number of third-party eblasts to our registered users.







Our 2024 schedule is open for bookings. Please contact **Jamie Cox** at jamie.cox@insights.bio.



PREMIUM SERVICES


We offer a number of premium options, both for content creation and for market research. These include:

- ▶ Bringing together KOL panels to discuss the topics of your choice, publishing the output as an ebook, video, and written roundtable, or other suitable content format
- ▶ Designing infographics, which can be animated and/or voiced, ideal for communicating complex technical or scientific information in an easily digestible format
- ▶ Inviting industry or academic Subject Matter Experts to join your live webinars to add their opinions to the discussion
- ▶ Building and deploying surveys amongst our users, providing detailed reports on the responses
- ▶ Bringing together focus groups to discuss your products/services, or topics of interest to you.



OUR OTHER PUBLICATIONS

In addition to *Immuno-Oncology Insights*, BioInsights also publishes:



Cell & Gene Therapy Insights

Launched in 2014, *Cell & Gene Therapy Insights* is our inaugural online, open access, peer-reviewed journal with a translational focus.

Cell & Gene Therapy Insights addresses the important challenges and advances in the field of cell and gene therapy, publishing original research, reviews, commentary articles, clinical trial reports and much more.

Vaccine Insights

Launched in 2022, *Vaccine Insights* is a peer-reviewed, open-access journal providing insights into development and manufacture of prophylactic and therapeutic vaccines. The journal brings together leading experts from pharma, biotech, academia and other key stakeholders to address critical issues and put the latest developments into context. Guided by an expert advisory board, the journal covers the most important advances in vaccine development and manufacture across all disease areas.

If you would like to distribute content to more than one of the cell & gene therapy, immuno-oncology and vaccine communities, we can promote it across multiple journals and market it to more than one set of users.

Nucleic Acid Insights

The latest addition to our publication portfolio, *Nucleic Acid Insights* provides online, peer-reviewed, open access content with a translational focus.

Nucleic Acid Insights is specifically designed to provide the need-to-know information required to successfully navigate this rapidly evolving space, covering all the major RNA and DNA technologies and modalities, including but not limited to: messenger RNA (mRNA); plasmid DNA; antisense oligonucleotides (ASO); phosphorodiamidate morpholino oligonucleotides (PMO); RNA interference (RNAi); small interfering RNA (siRNA); aptamers; micro RNA (miRNA); and guide RNA (gRNA).